Bioxyne’s Breathe Life Sciences (BLS) has successfully manufactured GMP THC gummies, fulfilling its first commercial run of edible cannabis products in Australia.
The range is made up of three medicines with different dosages of CBD and THC, with initial purchase orders underway and scheduled to be completed by mid-September.
In July, BLS received deposits on orders of around A$2 million and in the same month, the firm signed a two-year manufacture and supply agreement for a forecast minimum of $28m of the gummy products with “one of Australia’s largest cannabis companies”.
The company is scaling up its gummy manufacturing capabilities from two million single doses per month to six million to meet anticipated market demand.
Founder and CEO of BLS and managing director of Bioxyne Sam Watsom said: “As a leading Australian cannabis manufacturer, we are supplying our pharmaceutical goods to both domestic and international markets, using established relationships and existing supply channels.”
BLS general manager Jason Stephens added: “This is a significant milestone for Australian pharmaceutical manufacturing and the medical cannabis industry as a whole.”
Pastilles are gaining in popularity as a dosage form among doctors and patients according to data from the Therapeutic Goods Administration (TGA).
BLS said its GMP licence, granted by the TGA in February, makes it “a first mover in this emerging high-growth domestic market opportunity”.
